ARWR — ARROWHEAD PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 879407 ·
Last close
$42.99
Market Cap
$6.08B
52W High
$95.49
52W Low
$37.06
ADV30
2,088,755
Next earnings
2027-02-04
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 37,794,000 — -436,627,000 -428,001,000 1,738,257,000 62,735,000 1,687,753,000
Jun 2026 75,253,000 — -170,093,000 -194,280,000 2,112,013,000 19,685,000 1,645,972,000
Mar 2026 73,737,000 — -141,260,000 -132,732,000 2,268,265,000 147,531,000 1,669,349,000
Dec 2025 264,033,000 — 40,809,000 30,811,000 1,604,181,000 71,370,000 1,041,484,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-59,055,000
Investing CF
$-801,722,000
Financing CF
$784,187,000
CapEx
$-16,056,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.33
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,923,355,000
Inventory
—
Receivables
$8,556,000
ST Investments
$1,582,275,000
EBIT TTM
$-159,471,000
Pretax Income TTM
$-252,078,000
Interest Exp TTM
$92,607,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$450,816,992
EBITDA
$-680,548,992
Free Cash Flow
$-586,995,392
Enterprise Value
$6,973,346,304
Total Cash
$1,188,782,976
Total Debt
$1,407,374,976
Shares Out
141,368,004
Trailing EPS
$-5.11
Book Value
$0.36
ROE
-258.9%
ROA
-28.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Sep 2026 450,817,000 -707,171,000 -724,206,000 1,738,257,000 1,687,753,000 50,313,000 -271,949,000
Sep 2025 829,448,000 98,346,000 -1,631,000 1,385,295,000 881,879,000 466,052,000 179,552,000
Sep 2024 3,551,000 -601,080,000 -599,493,000 1,139,802,000 948,739,000 185,444,000 -462,851,000
Sep 2023 240,735,000 -205,002,000 -205,275,000 765,552,000 478,390,000 271,343,000 -153,890,000
Sep 2022 243,231,000 -178,507,000 -176,063,000 691,939,000 273,600,000 398,520,000 -136,131,000

TTM Snapshot

Revenues TTM
$669,495,000
NetIncome TTM
$-319,951,000
OpCashFlow TTM
—
Assets (Latest)
$2,112,013,000
Forward EPS
$-2.95

Max Pain — expiry 2026-12-18

max pain strike: $50.00 · spot: $43.11 · call oi: 5,496 · put oi: 1,612

Peers — same industry

TickerNameMarket CapLastDaily %
MIRM Mirum Pharmaceuticals, Inc. $6.00B $91.95 —
LGND LIGAND PHARMACEUTICALS INC $5.86B $293.81 —
BLTE BELITE BIO, INC $6.35B $157.72 —
ORKA Oruka Therapeutics, Inc. $6.53B $96.32 —
GIFLF Grifols SA $5.37B $12.72 —

News headlines (Yahoo Finance, 1h cache)

ARWR: Commercial Momentum Builds Ahead of Potential Expansion into sHTG Market
2026-11-18 11:02 · Yahoo
Could RNAi Trial Data Alter The Investment Case For Arrowhead Pharmaceuticals (ARWR)?
2026-11-18 01:10 · Yahoo
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-11-17 21:30 · Yahoo
Chardan revisits a top pick in biotech following fiscal 2026 results
2026-11-17 20:46 · Yahoo
Arrowhead Pharmaceuticals, Inc. Q4 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
Arrowhead (ARWR) Q4 2026 Earnings Call Transcript
2026-11-13 05:20 · Yahoo
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
2026-11-13 02:14 · Yahoo
Arrowhead Pharmaceuticals falls on earnings miss
2026-11-12 22:03 · Yahoo
Arrowhead Research: Fiscal Q4 Earnings Snapshot
2026-11-12 21:22 · Yahoo
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
2026-11-12 21:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.